Ozgene and Gen-H partner on Ozgene’s new OzBIG targeted humanization capability
PERTH, Australia & HEIDELBERG, Germany--(BUSINESS WIRE)--#biotechnology--Ozgene and Gen-H are pleased to announce our working partnership…
4 years ago
Wire Stories
Datasea’s Ultrasonic Sound Sterilization and Antivirus Equipment Confirmed by Leading Lab Achieved a 99.83% Efficacy in Nine Seconds Against Covid-19
BEIJING, July 21, 2022 (GLOBE NEWSWIRE) -- Datasea Inc., (NASDAQ: DTSS) ("Datasea" or the "Company"),…
4 years ago
Cell and Gene Therapy Industry Comes Together for Matica Bio’s New Global Event
COLLEGE STATION, Texas--(BUSINESS WIRE)--Matica Biotechnology, Inc. (Matica Bio), a contract development and manufacturing organization (CDMO)…
4 years ago
TCS World Travel Announces 2023 Expedition Schedule
Award-Winning Luxury Tour Operator and Private Jet Expedition Company Introduces New Roster of Nine International…
4 years ago
GomunoInaki Invests in Sustainable Development With Innovative SmartFlower Solar Solution
A leading-edge solution to provide clean energy for the community and to bring sustainability to…
4 years ago
ASM Global’s Asia Pacific Presence Expands With Announcement of Strategic Partnership With Malaysian Government for Kuala Lumpur Sports City Management
Largest Such Complex in Region Massive 87,400-Seat Malaysia National Stadium—Largest in Asia Outside North Korea—and…
4 years ago
Embassy REIT Announces Q1 FY2023 Results, Delivers Record 1.8 Million Square Feet of Total Leases
Achieves highest quarterly deal activity since April 2019 listing; signs 25 deals totaling 1.8 msf…
4 years ago
BYD Hits the Japanese Passenger Vehicle Market with Three EV Models
TOKYO--(BUSINESS WIRE)--On July 21, BYD JAPAN Inc., a branch of BYD Company Limited in Japan,…
4 years ago
Long Island University Reinvests in BIO-key’s PortalGuard Identity and Access Management Platform to Address Security Requirements at Multiple Campuses
BROOKVILLE, N.Y. and WALL, N.J., July 21, 2022 (GLOBE NEWSWIRE) -- BIO-key International, Inc. (NASDAQ:…
4 years ago
Takeda Announces Positive Topline Results from Pivotal Phase 3 Clinical Trial Evaluating HYQVIA® for Maintenance Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
- Data Show that HYQVIA® [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] Reduced…
4 years ago